Bullish & Foolish
Full RANI fundamentals All 466 on the Survival Watch

RANIRANI THERAPEUTICS HOLDINGS, INC.

Is Rani Therapeutics Holdings struggling financially?

Yes, by its own account. Rani Therapeutics Holdings told the SEC on 16 Apr 2026, in Form DEF 14A, that there is substantial doubt about its ability to continue as a going concern.

Going concern disclosed Apr 2026

15/100

Critical

Sector
Biotech/Pharma
Market cap
$122.7M
Source filing
DEF 14A 16 Apr 2026
Balance sheet
30 Jun 2026

Cash runway

  • 1month

    If the burn speeds up

    Empty by Jul 2026

  • 2months

    If it eases off

    Empty by Aug 2026

Both rows are the same reported burn flexed 15% either way, and neither assumes the company raises a cent.

Out of cashTwo years or more

The runway math

Cash and short-term investments

$4.9M

÷

Cash burned over the last 12 months

$40.9M

What Rani Therapeutics Holdings told the SEC

…report of the Company’s consolidated financial statements for the year ended December 31, 2024 contained an explanatory paragraph which noted that there was substantial doubt about the Company’s ability to continue as a going concern. During the fiscal year ended December 31, 2024, and the subsequent interim period through April 7, 2025, there have been no “disagreements” (as defined in Item 304(a)(1)(iv) of…

RANI THERAPEUTICS HOLDINGS, INC., Form DEF 14A, filed 16 Apr 2026.

Read the filing on SEC.gov

What this means

  • Not a bankruptcy filing, and not a prediction.
  • It is the company’s own statement, agreed with its auditor, that the doubt is material enough to disclose.
  • The runway is arithmetic on two reported numbers, not a forecast. Companies carry this language for years, raise money and keep going.

What else the numbers show

  • 414.4% share-count increase The company issued stock. Each share now owns 80.6% less of the business than a year ago, before any change in the price.
  • Cash burn is narrowing It is spending 30% less cash per year than it was, so the runway above is lengthening rather than shortening.

Other Biotech/Pharma companies that filed the doubt